Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, Yesterday
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.

Low-level silica exposure ups overall, cause-specific mortality risk

18 Sep 2017

Low-level occupational exposure to crystalline silica is associated with increased risk of mortality from respiratory diseases, pulmonary heart disease, lung cancer and ischaemic heart disease, among other complications, a new study has found.

The study included 44,087 Chinese workers (81.2 percent male) with histories of at least 1 year of pottery factory or metal mine work. Of these, 24,731 had never been exposed to silica and 20,076 had had a lifetime peak silica exposure of 0.35 mg/m3.

Participants who had ever been exposed to crystalline silica were further categorized into two according to the lifetime highest exposure: those with a lifetime peak exposure of ≤0.05 mg/m3 (n=4,038) and those with ≤0.10 mg/m3 (n=10,486).

Of participants in the ≤0.10 mg/m3 level, quartiles of silica exposure showed a significant and positive linear trend with overall mortality risk (hazard ratios [HRs] per quartile, 1.11, 1.23, 1.33 and 1.18; p<0.001 for linear trend).

Silica exposure also correlated significantly with higher mortality risks from malignant neoplasms (HR, 1.06; 95 percent CI, 1.03 to 1.09), lung cancer (HR, 1.08; 1.02 to 1.14), ischaemic heart disease (HR, 1.09; 1.02 to 1.16), pulmonary heart disease (HR, 1.08; 1.00 to 1.16) and respiratory disease (HR, 1.20; 1.14 to 1.26).

Trends were similar in the ≤0.05 and ≤0.35 mg/m3 level.

Over the follow-up period of 33.5 years, 8,506 all-cause deaths were reported, yielding an overall mortality rate of 594.0 per 100,000 person-years. The mortality rate for the group never exposed to silica was 550.7 per 100,000 person-years, while for those with a lifetime peak exposure of ≤0.35 mg/m3, the rate was 643.4 per 100,000 person-years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, Yesterday
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.